S_ummary Studies were carried out in a variant human multidrug-resistant (MDR) cell line CEM/A7R, which expresses very low levels of mdrl mRNA and P-glycoprotein (P-gp). The induction of mdrl RNA expression by three anthracycines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of mdrl expression was expressed as ratio of mdrl to the internal RNA (actin). A significant increase (P < 0.02) in expression of mdrl was noted within 4 hrs of exposure to 1.5 ig ml-' daunorubicin or epirubicin. Neither vinblastine nor vincristine had any effect on mdrl levels after an 8 h exposure. With increasing concentrations of daunorubicin or epirubicin in a fixed 24 h time period, mdrl expression increased, although a biphasic response was seen. Based on MRK 16 binding, an increase in P-gp levels was seen in the CEM/A7R line after a 24 h exposure to 1 Zig ml1 l daunorubicin or epirubicin. The rapid increase in mdurl expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdrl expression may have an important role in the development of drug-resistant tumours.
Multidrug resistance (MDR) is a common problem in acute leukaemia. Patients often relapse with unresponsive disease following an initial response to treatment with cytotoxic drugs. One form of drug resistance commonly seen in relapsed acute leukaemia is related to the overexpression of P-glycoprotein (P-gp), a marker of the classical MDR phenotype (Deuchars and Ling, 1989) . P-gp, encoded by the mdrl gene (Goldstein et al., 1992) , is believed to function as an energy-dependent, efflux pump resulting in the decreased accumulation of several structurally unrelated drugs including anthracyclines, vinca alkaloids and epipodophyllotoxins (Hayes and Wolf, 1990) . The classical MDR phenotype can be partially reversed by a wide range of structurally diverse compounds such as verapamil (Tsuruo et al., 1981; Ford and Hait, 1990 ) and cyclosporin A (Slater et al., 1986) .
A number of studies in human acute leukaemia have demonstrated that expression of the mdrl gene is usually low or undetectable before treatment but increased after chemotherapy. In addition, there appears to be a direct correlation between expression of the mdrl gene and the outcome of chemotherapeutic treatment (Chan et al., 1990; Goasguen et al., 1993) .
The acquisition of drug resistance during chemotherapy is usually thought to be due to the selection of drug-resistant cells. In human cells, rapid up-regulation of ,ndrl expression by cytotoxic drugs has not been demonstrated by conventional hybridisation techniques. Immunocytochemical staining with the monoclonal antibody (MAb) MRK16 in a human pleural mesothelioma line (Licht et al., 1991) or MAb C219 in a human lung adenocarcinoma line (Chevilard et al., 1992) has only shown an increase in the number of P-gppositive cells after several weeks of treatment with anticancer drugs. However, overexpression of mdrl in rodent but not human cells (Chin et al., 1990a) was seen 8 h following treatment with cytotoxic drugs, suggesting an important but unexplained difference in the regulation of mdrl expression between human and rodent tissues. More recently, using the highly sensitive polymerase chain reaction (PCR) assay, increased expression of human mdrl was observed 3-5 days following cytotoxic drug treatment, a period defined by microscopically visible cell damage (Chaudhary and Roninson, 1993) .
In contrast, mdrl expression has been shown to be rapidly inducible in human cell lines in response to heat shock, arsenite (Chin et al., 1990b; Kioka et al., 1992a) or differentiating agents Mickley et al., 1989) . Using a CAT (chloramphenicol acetyltransferase) assay, the proximal promoter of the mdrl gene may be directly activated by some cytotoxic drugs (Kohno et al., 1989) , as well as heat shock (Kioka et al., 1992b; Miyzaki et al., 1992) , serum deprivation and differentiating agents Ferrandis and Benard, 1993) . However, the relevance of this change in the function of an exogenous promoter linked to a reporter gene is uncertain in view of the difficulties in detecting up-regulation of the endogenous mdrl gene following the administration of cytotoxic drugs Ferrandis and Benard, 1993) .
The apparent species differences in the response of the mdrl gene to exposure to anthracyclines led us to examine this issue more carefully in a variant MDR cell line in order to determine whether human mdrl gene expression was inducible. Using Northern blotting, the induction of mdrl by three anthracyclines, doxorubicin (DOX), daunorubicin (DAU) and epirubicin (EPI), and two vinca alkaloids (vincristine and vinblastine) was investigated in a cloned, variant cell line CEM/A7R known to express low levels of P-gp. A rapid induction of mdrl was observed, suggesting that in this model P-gp expression was inducible and, thus, by inference, that the development of clinical drug resistance may involve both the induction and selection of drug-resistant cell populations. resuspended at a total cell number of 5 x 106 to 1 x 107 in 20 ml of fresh medium. The cells were treated with either DOX, EPI, DAU VP-16, VIN or VLB and harvested at designed time points. Cell viability was determined (after staining by trypan blue) using phase-contrast microscopy to detect cells of abnormal size or granularity. Non-viable cells were excluded from flow cytometric analysis by propidium iodide (Sigma) staining.
Materials and methods

Materials
Growth assays
The sensitivity of each of the cell lines to a variety of chemotherapeutic drugs was determined by a standard growth inhibition assay (Tsuruo et al., 1981) . Briefly, after determining cell viability and adjusting the final concentration of cells in flat-bottomed 12-well plates to 2 x 10 ml-', varying concentrations of DOX, DAU or EPI were added to each well. The cells were incubated in humidified chambers at 37C for 3 days and counted using an automated Coulter counter (Hu et al., 1990) . Results are expressed as the increase in cell numbers in drug-exposed cells as a percentage of the increase in control cells (Tsuruo et al., 1981 (Figure la ). After the data had been normalised with respect to the CCRF-CEM signal, the baseline ratios of mdrl to the internal RNA control, E-actin, were 0.% and 0.20 for the CEM/A7 and CEM/A7R lnes respectively (Figure lb) . Equal concentrations of all drugs were used for the purpose of comparison. The concentrations used were generally greater than the IC50 of each of these agents when tested in a standard 3 day growth assay (see Table I ). Following an 8 h exposure to 1.5 pg ml-' DOX, DAU, EPI, or VP16, the ratio of mdrl/actin expression in the CEM/A7R cells (compared with the untreated control) increased 2-to 4-fold (Figure la  and b) . However, after a similar time period, neither VLB nor VIN had any effect on mdrl expression.
Experiments over a shorter time using fixed drug concentrations of 1.5lzgml-' were then conducted. Results were quantitated as described above and the data expressed as the ratio of mdrl expression to the internal RNA (actin) control (Table IL) (Figures 2 and 3) and DAU ( Figure   3 ).
Drug-treated cells were carefully examined microscopically (after staining with trypan blue) for visible cell damage as evidenced by changed cell shape and/or increased granularity.
In the MRK16 binding experiments, cell viability was estimated simultaneously by using propidium iodide staining.
No evidence of cell damage or alterations in cell viability was observed (data not shown).
TIhe effect of the increase in mdrl mRNA levels on the expression of P-gp was examined using flow cytometry. CEM/A7R cells expressed significantly less P-gp than the (Figure 4 ). Exposed to 1 jig ml-' EPI or DAU, CEM/A7R cells showed a 3-to 4-fold increase in P-gp expression (mean channel fluorescence 177 and 144 respectively) compared with untreated CEM/A7R cells (mean channel fluorescence 45). The stability of the increased levels of mdrl and P-gp expression in response to DOX was tested 3 weeks after the CEM/A7R cells had been exposed to 1 ,Lg rl' DOX for 24 h. The treated cells were cultured in drug-free medium for 3 weeks before being subjected to a further analysis of mdrl CEM/A7 Fugwe 4 Flow cytometric analysis of P-gp expression using MRK-16 binding (filled histogram) compared with an IgG2, control (unfilled histogram) in the CCRF-CEM, CEM/A7 and the CEM/A7R lines before and after exposure to EPI or DAU. P-gp expression was not seen in the CCRF-CEM parental cell line. CEM/A7R expressed much less P-gp (10-fold) than the CEM/A7 line. CEM/A7R cells were treated with (or without) 1.5ILg ml-' of EPI and DAU for 24 h before measurement of P-gp levels as described in Materials and methods. P-gp expression was increased more than 3-fold in the treated CEM/A7R cells compared with untreated controls. hi no developed Dy contunuous culture ot tne CLM/Al hne m me absence of DOX. The subcloned variant cell line labelled CEM/A7R was stable in drug-free medium for over 12 months before conducting the experiments reported in this study. The CEM/A7R line expressed P-gp to a significantly lesser extent than the classical MDR line from which it was derived (Figures 1 and 4) . This line appears to be a useful model for studying clinical drug resistance in so far as it does not have detectable amplification of the mdrl gene and expresses very low levels of P-gp in the absence of a continuous selective pressure.
In order to assess the effects of cytotoxic drugs on mdrl expression, the ratio of mdrl RNA to an internal RNA (actin) control was quantitatively analysed following the exposure of cells to various drugs by scanning Northern blots on a phosphorimager. A significant increase (2-fold) in mdrl expression was observed within 4 h of exposure of CEM/ A7R cells to 1.5 1Lg ml-' DAU or EPI and 6 h to 1.5Lrg ml-' DOX (Table II) 1.oo 1.20 was observed after an 8 h exposure to 1.5 )g ml-' DOX, nconcentration (gg mr1) DAU or EPI (Figure la and b) . Increases in mdrl levels also resulted in an increase in P-gp expression (Figure 4) (Chin et al., 1990b; et al., 1990a _4r lL-I-IIClkff /A '7 1:__ :_ L.-
